OptimizeRx (NASDAQ:OPRX) to Buyback $10.00 million in Stock

OptimizeRx (NASDAQ:OPRX) announced that its Board of Directors has approved a share buyback program on Thursday, March 5th, RTT News reports. The company plans to buyback $10.00 million in shares. This buyback authorization permits the company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its stock is undervalued.

OptimizeRx Trading Down 4.3%

OptimizeRx stock opened at $7.53 on Friday. The firm has a market cap of $140.36 million, a PE ratio of 19.67 and a beta of 1.20. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The stock’s 50 day simple moving average is $10.63 and its two-hundred day simple moving average is $14.80. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20.

OptimizeRx (NASDAQ:OPRX) last posted its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. Analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on OPRX. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Stephens dropped their target price on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Monday, November 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Finally, Citizens Jmp increased their price objective on shares of OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.50.

Key Stories Impacting OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings beat — OptimizeRx reported Q4 EPS of $0.51 vs. the Zacks consensus of $0.23, a clear upside that underscores recent operating leverage and drove upbeat commentary in the release. OptimizeRx Q4 Earnings Beat (Zacks)
• Positive Sentiment: Share repurchase authorized — The Board approved a $10.0M buyback program (up to ~6.8% of shares), a signal management believes the stock is undervalued and a potential support for the share price over time. Buyback Announcement (RTT News)
• Neutral Sentiment: Full-year 2025 results and company commentary — Management published a detailed Q4 and FY‑2025 results release highlighting business trends and performance drivers; useful for modeling but largely confirms the EPS beat story. Company Results (GlobeNewswire)
• Neutral Sentiment: Earnings call/transcript available — Transcripts and call coverage add detail on market dynamics, client trends and margin outlook; they help investors assess whether the guidance shift is structural or temporary. Earnings Call Transcript (Yahoo) Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Cautious FY‑2026 revenue guidance — Management set 2026 revenue at $109M–$114M, below the consensus (~$122M). That guidance reset, driven by market shifts per management, is the primary catalyst for the intraday selloff as it suggests slower top‑line growth than analysts expected. FY‑2026 Guidance (Seeking Alpha)

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.